期刊
BLOOD
卷 127, 期 9, 页码 1097-1101出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-09-625343
关键词
-
类别
资金
- Cancer Research UK and Bloodwise
- EU
- Cancer Research UK [20537, 10834, 18518] Funding Source: researchfish
Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not all tumors respond, and agent optimization is essential to improve outcome. It has become clear over recent years that isotype choice is vital to therapeutic success with agents that work through different mechanisms, direct tumor targeting, agonistic receptor engagement, or receptor-ligand blockade, having contrasting requirements. Here we summarize how isotype dictates mAb activity and discuss ways in which this information can be used for the development of enhanced therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据